durvalumab
astrazeneca
update of topaz-1 at #wcgci2022 by gemcis and durva in #cholangiocarcinoma no impact of tumor location on impact outcome and efficacy for iccc: 15.5 vs. 11.0
ecca: 12.7 vs 12.1 what about gallbladder?
10.7 vs 11.0 (small subgroup) 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine